Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series C brings in $60mm for Dicerna

Executive Summary

RNAi therapeutics developer Dicerna Pharmaceuticals Inc. brought in $60mm through an oversubscribed Series C financing led by first-time backer RA Capital, which adds a board member and was joined by other new investors Brookside Capital, Deerfield, and Omega Funds, and returning shareholders Abingworth Management, Domain Associates, Oxford Bioscience Partners, Skyline Ventures, and SR One. Funds will be used to advance two or more programs into clinical trials (expected in early 2014) and for ongoing work on preclinical candidates.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Site Specific
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
    • Nanotechnology, Chips, etc.
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies